Safety and economic evaluation of patients treated for hepatitis with antiviral daclatasvir and sofosbuvir combined Vs. Ledipasvir/ sofosbuvir 90mg/400mg in a medical institution in the U.A.E

Aims:The pharmacoeconomic evaluation of Hepatitis C Virus (HCV) medications is necessary to assess the clinical benefits and cost-effectiveness of newer treatments for chronic (HCV) infection. This study determines the cost-effectiveness of Daclatasvir and Sofosbuvir compared with Harvoni (Ledipasvir/Sofosbuvir 90mg/400mg) which is a current treatment for Chronic Hepatitis C (CHC). Me thods: A retrospective quantitative comparative study was carried out by comparing patients’ related health and economic status of HVC on two specific regimens; the first regimen is “Daclatasvir plus Sofosbuvir in patients infected with HCV. The second regimen is “Harvoni” once daily for 12 weeks. Data was collected anonymously from electronic patients’ files. Results:The use of Sovaldi 400mg and Daklinza 60mg compared to Harvoni alone was cost-effective due to the decreased frequency of concomitant disease progression and their associated costs. The clinical outcome of groups A & B, showed some differences in viral load in the first few weeks which was equalized by continued treatment for 8 weeks. Conclusion:Sofosbuvir- and Ledipasvir-based treatments would significantly lessen the clinical burden of HCV. The new treatments are more cost-effective for patients who have HCV genotype 1, are newly infected, or are younger.